Medinet CoTSE:2370 41 EBITDA Margin % is -104.66% as of Mar. 2026. GuruFocus rates TSE:2370 with a GF Score™ of 41/100 and a GF Value™ of 円41.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 939 Biotechnology companies, Medinet Co ranks worse than 57.51% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medinet Co's EBITDA for the
three
months ended in Mar. 2026 was 円-243.7 Mil. Medinet Co's Revenue for the
three
months ended in Mar. 2026 was 円232.9 Mil. Therefore, Medinet Co's EBITDA margin for the quarter that ended in Mar. 2026 was -104.66%.
Medinet Co (TSE:2370) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medinet Co EBITDA Margin % Related Terms
Medinet Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medinet Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Medinet Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medinet Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinet Co (TSE:2370) has a EBITDA Margin % of -104.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medinet Co and its competitors. According to the industry distribution chart, Medinet Co ranks #540 out of 939 companies in the Biotechnology industry, placing it in the top 57.5%.
Is Medinet Co's EBITDA Margin % too high?
Medinet Co's current EBITDA Margin % is -104.66%. Based on the distribution chart, Medinet Co ranks #540 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #540 out of 939 companies for EBITDA Margin %. This places Medinet Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medinet Co and its competitors. Medinet Co's current EBITDA Margin % is -104.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.74, compared to a current price of 円25.00 — trading 40.1% below its estimated fair value. The current EBITDA Margin % is -104.66%. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current EBITDA Margin % is -104.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40.1% below its estimated GF Value™ of 円41.74.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
EBITDA Margin %: -104.66%
GF Value™: 円41.74 vs. price of 円25.00 (40.1% below fair value)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score
Get the complete analysis for TSE:2370
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
